

1 **Dietary sulfur amino acid restriction in humans with overweight and obesity:**
2 **a translational randomized controlled trial**

3

4 Thomas Olsen^{1,a,*}, Emma Stolt^{1,a}, Bente Øvrebø², Amany Elshorbagy^{3,4}, Elena C. Tore⁵,
5 Sindre Lee-Ødegård⁶, Hannibal Troensegaard¹, Hanna Johannessen⁷, Beate Doeland¹, Anna
6 A. D. Vo¹, Anja F. Dahl¹, Karianne Svendsen^{1,8}, Magne Thoresen⁹, Helga Refsum^{1,4}, Russell
7 Rising¹⁰, Kristýna Barvíková¹¹, Marleen van Greevenbroek⁵, Viktor Kožich¹¹, Kjetil
8 Retterstøl^{1,8}, Kathrine J. Vinknes¹

9 ¹ Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo,
10 Norway

11 ² Department of Food Safety, Norwegian Institute of Public Health, Oslo, Norway

12 ³ Department of Physiology, Faculty of Medicine, University of Alexandria, Alexandria,
13 Egypt

14 ⁴ Department of Pharmacology, University of Oxford, UK,

15 ⁵ Department of Internal Medicine and CARIM School of Cardiovascular Diseases,
16 Maastricht University, Maastricht, The Netherlands

17 ⁶ Department of Clinical Medicine, Faculty of Medicine, University of Oslo

18 ⁷ Department of Paediatric Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway

19 ⁸ The Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine,
20 Oslo University Hospital, Oslo, Norway

21 ⁹ Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo,
22 Norway

23 ¹⁰ D&S Consulting Services, Inc., New York, USA

24 ¹¹ Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine,
25 Charles University and General University Hospital, Prague, Czech Republic.

26 ^a Shared authorship.

27

28 *Correspondence: Thomas Olsen, thomas.olsen@medisin.uio.no

29 **Abstract**

30

31 Dietary sulfur amino acid restriction (SAAR) improves metabolic health in animals, but in
32 humans, SAAR has not been investigated in translational clinical trials. In this study, we
33 investigated the effect of dietary SAAR on body weight, body composition, resting metabolic
34 rate, gene expression profiles in white adipose tissue (WAT), and an extensive blood
35 biomarker profile in 59 humans with overweight and obesity in a double-blind, randomized
36 controlled trial (ClinicalTrials.gov: NCT04701346). Participants were randomized to a plant-
37 based diet low (~2 g/d, SAAR) or high (~5.6 g/d, control group) in sulfur amino acids. The
38 diets were provided in full to the participants. After 8 weeks of intervention, SAAR led to a
39 ~20 % greater weight loss compared to controls (β (95 % CI) -1.14 (-2.04, -0.25) kg, $p =$
40 0.012). Despite greater weight loss, resting metabolic rate remained similar between groups.
41 Furthermore, SAAR decreased serum leptin, and increased ketone bodies compared to
42 controls. In WAT, 20 genes were upregulated whereas 24 genes were downregulated (FDR <
43 5 %) in the SAAR group compared to controls. Generally applicable gene set enrichment
44 analyses revealed that processes associated with ribosomes were upregulated, whereas
45 processes related to structural components were downregulated. In conclusion, our study
46 shows that SAAR leads to weight loss and metabolic benefits. Further research SAAR is
47 needed to investigate the therapeutic potential for metabolic conditions in humans.

48

49 **1. Introduction**

50

51 Methionine and cysteine are essential and semi-essential sulfur amino acids (SAA) with a
52 FAO/WHO minimum (recommended) intake of 15 (19) mg/kg/d in adults¹. High dietary
53 intake and plasma concentrations of SAA are strongly and linearly related to increased risk of
54 metabolic disease and development of obesity²⁻⁹. In a large population-based cohort study of
55 men and women (n = 5179), the difference in fat mass between lower and upper percentiles of
56 plasma total cysteine (tCys) was 11 kg³. Moreover, in two independent Dutch cohorts of men
57 and women aged 40–74 y, plasma methionine was associated with liver fat, whereas tCys was
58 associated with overall obesity⁹. Recent prospective cohort studies showed that plasma tCys
59 was associated with diabetes risk¹⁰, whereas dietary intake of SAA was associated with
60 increased cardiovascular risk scores, diabetes risk and diabetes-related mortality⁶⁻⁸.

61 Dietary sulfur amino acid restriction (SAAR) has been investigated in experimental
62 animal studies for 30 years, and has been shown to have numerous beneficial effects on
63 metabolic health including reduced body weight, improved body composition and insulin
64 sensitivity, and increased energy expenditure¹¹⁻²¹. In addition, SAAR is associated with
65 changes in several blood biomarkers including decreased leptin and triglycerides, and
66 increased ketone bodies and adiponectin^{12-14,22-24}. These SAAR-induced effects are triggered
67 by metabolic adaptations, including mitochondrial biogenesis and transcriptional remodeling of
68 lipid and glucose metabolism in several tissues, but especially in white adipose tissue (WAT)
69 and liver¹⁷. Important mediators of these effects include the liver hormones fibroblast growth
70 factor 21 (FGF-21)^{25,26} and insulin-like growth factor 1 (IGF-1)^{27,28}.

71 Despite these robust findings in experimental and observational studies, dietary
72 interventions with SAAR in humans at risk of metabolic disease are scarce²⁹⁻³¹. Of these, only
73 one long-term, double-blind randomized controlled trial has been published³⁰. This 16-week
74 study implementing dietary methionine restriction with a mostly powder-based diet

75 demonstrated increased fat oxidation and decreased liver fat. However, there was a lack of
76 adherence and a high dropout-rate partly due to the synthetic nature of the diet.

77 To increase palatability and adherence to a SAAR regimen, we developed an approach
78 using plant-based whole foods. Results from two double-blind one-week pilot studies using
79 this approach indicated that some metabolic effects on plasma and urinary SAA, FGF-21, and
80 adipose tissue gene expression were apparent in humans within one week^{31,32}. Building on
81 previous data from animals and humans, we performed an 8-week double-blind randomized
82 controlled dietary intervention in individuals with overweight and obesity. Our primary aim
83 was to study the effects of SAAR on body weight. In addition, we assessed the effects of
84 SAAR on several exploratory outcomes, including body mass compartments, energy
85 expenditure, metabolic biomarkers, adipokines and appetite-related hormones, and adipose
86 tissue gene expression profiles.

87

88 **2. Results**

89 Baseline characteristics, effect sizes and standard errors (SE) from intention-to-treat (ITT)
90 analyses are presented in **Tables 1 to 4** and **Figures 1 to 3**. Raw observed means and
91 estimated marginal means (EMMs) derived from the regression models for all variables and
92 all study visits are presented in the online supplement for the ITT population (**Supplemental**
93 **Tables S3 to S5**). All per-protocol (PP) analyses excluding drop-outs are presented in the
94 online supplement (**Supplemental Tables S6 to S8**).

95

96 *2.1. Participant flow and baseline characteristics*

97 A detailed participant flow is presented in **Supplemental Figure S1** and a simplified
98 overview in **Figure 1A**. In total, 61 individuals were randomized to SAAR (n = 32) or control
99 (n = 29). Two participants dropped out pre-baseline resulting in a total of 59 participants with
100 baseline visits who were analyzed ITT (SAAR n = 31; controls n = 28). Five additional drop-
101 outs during the course of the trial led to a total of 54 completers who were analyzed PP
102 (**Supplemental Tables S6 to S8**).

103 Baseline characteristics of the participants are presented in **Table 1**. There was an
104 equal number of men (n = 8) in each group, and the mean (SD) age of the participants was
105 33.2 (5.86) y in the SAAR group and 34.4 (6.26) y in controls. There was a difference of ~6
106 kg in baseline body weight between groups (SAAR, mean (SD) 94.4 (10.7); controls, 88.7
107 (9.22) kg), whereas mean (SD) body fat % was similar (SAAR, 42.0 (6.76); controls, 42.4
108 (5.80)). All other covariates were comparable between groups.

109

110 *2.2. SAAR reduces urinary sulfate excretion compared to controls*

111 The effects of SAAR on urinary excretion of the compliance biomarker sulfate are presented
112 in **Figure 1B** and **Table 2**. Twenty-four-hour urinary excretion of sulfate decreased in the

113 SAAR vs. control group after 8 weeks (β (95 % confidence interval [CI]) -20.2 (-24.9, -15.6)
114 mol/24 h, $p < 0.001$).

115

116 *2.3. SAAR reduces body weight but not resting energy expenditure compared to controls*

117 The effects of SAAR on body weight, body composition, energy expenditure and substrate
118 oxidation are presented in **Figure 1C-D** and **Table 2**.

119 Both groups lost weight during the intervention. On average, the SAAR group lost
120 1.14 kg more body weight compared to controls after 8 weeks (β (95 % CI) -1.14 (-2.04, -
121 0.25) kg, $p = 0.012$). No conclusive differences between groups were observed for body fat %.

122 For body composition, BMI and total fat free mass were reduced in the SAAR group
123 compared to controls (**Table 2**). Reductions in gynoid and subcutaneous adipose tissue mass
124 were also observed in the SAAR group compared to controls, but these findings were
125 inconclusive. There were no differences between groups in other regional adipose tissue
126 depots (arm fat, leg fat, trunk fat, android adipose tissue, visceral adipose tissue). Because loss
127 of fat mass and fat free mass directly depend on absolute weight loss, we further adjusted
128 these outcome models for total weight loss. This adjustment attenuated the observed
129 differences between groups, and the effect on fat free mass was no longer statistically
130 significant (data not shown).

131 Fat free mass-adjusted resting metabolic rate (RMR) was reduced similarly in both
132 groups after 8 weeks. Fat oxidation increased in the SAAR group compared to controls after
133 four weeks (β (95 % CI) 20.0 (1.82, 38.2) g/d, $p = 0.031$). This effect on fat oxidation
134 remained elevated but was attenuated after eight weeks in SAAR vs. controls (β (95 % CI)
135 12.8 (-5.12, 30.7) g/d, $p = 0.16$). No conclusive differences between groups were observed for
136 respiratory quotient (RQ) or glucose oxidation.

137

138 *2.4. SAAR reduces serum leptin and increases plasma ketone bodies*

139 The effects of SAAR on plasma hormones and biomarkers are presented in **Table 3** and
140 **Figure 1E-F**. There was a greater decrease of serum leptin in SAAR vs. controls (β (SE) -
141 6.01 (-11.4, -0.59) ng/mL, $p = 0.03$) after eight weeks, whereas no conclusive effects were
142 observed for other hormones, including FGF-21, IGF-1, adiponectin, and satiety hormones
143 (**Table 3**).

144 Both groups increased their serum concentrations of ketone bodies (**Figure 1F, Table**
145 **3**). The increase in plasma concentrations of β -hydroxybutyrate and acetoacetate was greater
146 in SAAR compared to controls, whereas a trend for a greater increase was observed for
147 acetone.

148 There were no effects of SAAR on classical metabolic risk biomarkers including the
149 plasma/serum lipid profile, glucose metabolism, or any safety markers with the exception of
150 creatinine; a decrease in serum creatinine was observed in the control group, but remained
151 unchanged in the SAAR group (**Table 3**).

152

153 *2.5. SAAR reduces urinary excretion of SAA*

154 The effects of SAAR on urinary excretion and plasma concentrations of SAA are presented in
155 **Figure 2A-B** and **Table 3**. Twenty-four-hour urinary output of methionine, total
156 homocysteine (tHcy), cystathionine, and tCys decreased in SAAR compared to controls
157 (**Figure 2A**). In plasma, concentrations of tHcy increased and plasma cystathionine decreased
158 in the SAAR group vs. controls (**Figure 2B**). No conclusive effects were observed for plasma
159 methionine and tCys.

160

161 2.6. SAAR affects adipose tissue gene expression

162 WAT was available from n = 51 participants at baseline and after eight weeks. In total, 44
163 genes were differentially expressed at a false discovery rate of 5 % (**Figure 3** and **Table 4**).
164 The full list of genes is available as a supplemental file (**Supplemental File 1**). Twenty-four
165 genes were significantly downregulated including *HSFX2*, *ESM1*, *SIK1B* and *APLN*. Twenty
166 genes were significantly upregulated, including *HIST2H4A*, *ARID5B*, *CYP4B1* and *ADH1B*.
167 The top 10 upregulated and downregulated gene ontologies as identified by generally
168 applicable gene set enrichment (GAGE) analyses are presented in **Figure 3B** and **3C**. GAGE
169 analysis revealed that gene ontologies related to ribosomes were upregulated whereas gene
170 ontologies related to transcription regulation and membrane components were downregulated
171 (FDR < 5 %).

172

173 **3. Discussion**

174 *3.1. Principal findings*

175 In this double-blind randomized controlled dietary intervention study, we aimed to investigate
176 whether effects of SAAR identified in various animal species over the past 30 years could be
177 translated to humans. Our main findings were that dietary SAAR recapitulates some of these
178 benefits in adult humans with overweight and obesity compared to controls, including
179 decreased body weight, BMI, and serum leptin concentrations, and increased plasma
180 concentrations of the ketone bodies β -hydroxybutyrate and acetoacetate¹¹⁻²⁴. In addition,
181 dietary SAAR affected gene expression in WAT.

182

183 *3.2. SAAR, body weight and energy expenditure*

184 We are the first to demonstrate that dietary SAAR with a plant-based diet leads to greater
185 weight loss compared to controls in a double-blind trial with matching diets between the
186 intervention and control groups. This is in contrast to the only other such study with
187 methionine restriction in humans at risk of metabolic disease³³, and may in part be explained
188 by the lower drop-out rate in the present study, with a key difference being our whole-food
189 approach and provision of the full study diet. The weight loss effect in both groups in the
190 present study is comparable to other dietary interventions with vegan diets³⁴, and our study
191 suggests that SAAR may add to this effect. The mechanisms behind this additive effect of
192 SAAR on body weight in humans are unknown. However, despite greater weight loss with
193 SAAR, there were no clear differences in RMR between groups. These findings are partly in
194 line with animal studies, where SAAR increases 24-h energy expenditure despite lower body
195 weights^{12,14,23,26,35}. Comparable to the previous study with methionine restriction in humans³³,
196 we observed a significant increase in fat oxidation after 4 weeks. Although this effect was
197 attenuated after 8 weeks, fat oxidation remained elevated as further supported by the elevated

198 plasma concentrations of ketone bodies in the SAAR group compared to controls.
199 Collectively, the effects of SAAR on body weight may involve regulation of RMR and
200 substrate oxidation, but these effects need to be confirmed in future studies.

201

202 3.3. SAAR and leptin

203 Our results are in line with several animal studies showing that SAAR decreased circulating
204 leptin concentrations^{12,17,22,23} and *Lep* expression in adipose tissue³⁶. In rodents, decreases in
205 circulating leptin concentrations correlates with decreased visceral fat mass and body weight
206 ¹². In humans, leptin plays a role in body weight regulation and food intake, and it has been
207 suggested that decreased leptin signaling after weight loss precede adaptive thermogenesis,
208 decreased RMR and increased fat oxidation^{37,38}. If so, the decrease in serum leptin in the
209 present study may be a result of the weight loss differences between groups, and not directly
210 due to SAAR. However, one rodent study showed that SAAR, when compared to calorie
211 restriction, reduced mRNA and plasma levels of leptin¹⁴, indicating that SAAR may have
212 distinct effects on leptin in humans. Notably, there were no effects of SAAR on WAT *LEP*
213 expression in the present study.

214

215 3.4. Biomarkers of SAA intake

216 We show for the first time that urinary output of sulfate, an end-product of methionine and
217 cysteine metabolism, decreases significantly with SAAR. Taken together with the strong
218 effects of SAAR on urinary excretion of SAA and related metabolites, the finding on sulfate
219 indicates excellent participant adherence in both groups. The less conclusive effects of diet on
220 plasma methionine and tCys were expected based on similar findings in previous trials and
221 large cohorts³⁹⁻⁴⁴. The lack of effects on plasma SAA indicate that dietary SAAR activates
222 compensatory mechanisms to maintain availability of particularly cysteine⁴⁵. Indeed, taurine

223 and glutathione metabolism are altered in mice on low-cysteine diets to maintain cysteine
224 availability^{46,47}, but whether any such processes are active in humans is not known. Future
225 studies are needed to fully understand the effects of dietary SAAR on circulating and urinary
226 sulfur-containing metabolites in humans.

227

228 3.5. SAAR and WAT gene expression

229 This is the first study to demonstrate effects of SAAR on WAT gene expression profiles using
230 a transcriptome-wide approach in humans. Altered gene expression plays a key role in
231 adipose tissue remodeling during SAAR in animals. Among the downregulated genes were
232 *APLN* and *ESMI*, which have been shown to be positively correlated with fat mass^{48,49}.
233 Moreover, several genes encoding proteins involved in lipogenesis such as *GPAM*, *ELOVL5*
234 and *DGAT2* were downregulated. The latter finding is in contrast to animal studies, which
235 have reported increased lipogenic gene expression in adipose tissue in conjunction with
236 increased beta-oxidation, and decreased lipogenic gene expression in liver¹⁷. The reason for
237 this discrepancy is unknown but may be driven by the greater weight loss in the SAAR group.
238 Furthermore, GAGE analyses revealed that SAAR was associated with a seemingly
239 paradoxical regulation of GO terms: SAAR was associated with upregulated cytoplasmic
240 translation, but decreased transcription regulation complex, both of which are implicated in
241 protein synthesis. In animals, SAAR slows overall protein synthesis⁵⁰, but a recent publication
242 outlines a complicated and dynamic machinery in which ribosomal proteins may be both
243 upregulated and downregulated, possibly reflecting a shift in metabolic processes during
244 SAAR⁵¹. However, these processes were studied in animal livers, and does not necessarily
245 reflect processes in human WAT.

246

247 *3.6. SAAR and fat free mass*

248 In the present study, the SAAR group experienced a greater loss of fat free mass comparison
249 to controls, a finding that is consistent in animal studies with diet-induced obesity⁵². To
250 account for the possibility that this was due to the greater loss of total body weight with
251 SAAR, we created an additional statistical model with adjustment for weight loss. No
252 conclusive effects of SAAR on body mass were found in these models, indicating that the
253 relative loss of fat free mass to loss of total body mass did not differ between the SAAR and
254 control groups. This is further reflected in the lack of observed effects on body fat %.
255 Nevertheless, loss of lean mass is generally not preferable during weight loss, and physical
256 activity should be considered as a co-intervention to maintain lean mass during weight loss
257 with SAAR. It is important to note that we were unable to differentiate between fat free mass
258 compartments (including total body water), and that the predicted loss of approximately 4.3 %
259 of fat free mass in the SAAR group is comparable to other interventions with calorie
260 restriction⁵³.

261

262 *3.7. Discrepancies with human and animal studies*

263 A recent controlled feeding study in humans²⁹ demonstrated several benefits of SAAR after 4
264 weeks compared to methionine restriction alone, including reductions in body weight and
265 plasma levels of total cholesterol, LDL, uric acid, leptin, and insulin, blood urea nitrogen, and
266 IGF-1, and increases in body temperature and plasma FGF-21 after 4 weeks. Such effects
267 have also been demonstrated in the animal literature^{12-14,22-28}. Although a number of these
268 parameters changed *within* the SAAR group in the present study, there were few differences
269 compared to the control group receiving a diet with identical macronutrient composition with
270 the exception of SAA. Expected phenotypical changes that were not reproduced with SAAR
271 in the present study, included differences in fat mass, improved plasma biomarker profile,

272 increased serum concentrations of FGF-21 and adiponectin, and decreased IGF-1^{20,22,24–28,54,55}.
273 These inconsistencies between studies may be due to differences in study designs, control
274 groups, and macronutrient composition. It should also be considered that there are
275 fundamental differences between the composition of dietary SAAR diet used in animals and
276 in humans that may be the reason for the observed discrepancies, limiting the degree of
277 translation across species. Notably, SAAR diets in animals are completely devoid of cysteine,
278 which is impossible to achieve in human diets using whole foods. For example, in rats,
279 cysteine restriction without methionine restriction produced large fluctuations in circulating
280 FGF-21, and cysteine restriction alone appears to be the main driver of the adiponectin
281 response to SAAR⁵⁶. In addition, methionine restriction without cysteine restriction reverses
282 several of the beneficial metabolic effects of SAAR⁵⁷. Therefore, our inability to eliminate
283 cysteine from the diet may partly explain some of the inconsistent results compared to the
284 animal literature. It has additionally been shown that a switch to a vegan diet produces large
285 increases in circulating FGF-21 in humans⁵⁸. Thus, the vegan base diet in both groups in the
286 present study may have obscured the expected SAAR response in serum FGF-21.

287 Another unexpected result in the present study was the increased serum IGF-1
288 concentrations in both groups. In the animal literature, decreased IGF-1 signaling is a key
289 mediator of the lifespan-extending effects of SAAR^{27,28}. In humans, circulating IGF-1
290 decreases with protein restriction⁵⁹. However, moderate energy restriction with resulting
291 weight loss, may actually increase circulating concentrations of IGF-1^{60,61}, but such results are
292 not consistent⁶². Compared to animal studies where SAAR diets are consumed *ad libitum*,
293 some level of energy restriction was inevitable in our study with fixed energy intakes of
294 ~2200/2500 kcal/d for women/men in both groups. As noted by others³³, the effect of weight
295 loss, in both groups, may have obscured potential SAAR-induced effects on circulating IGF-1
296 and other blood biomarkers. The particular issue with energy restriction and weight loss

297 requires novel approaches to SAAR in humans to capture more of its beneficial metabolic
298 health effects and to increase clinical relevance. Interestingly, a recent study by Plummer &
299 Johnson demonstrated that intermittent SAAR reproduced most, if not all benefits of
300 continuous SAAR²⁴. Intermittent SAAR presents an attractive approach for future clinical
301 trials in humans, in which SAAR could be applied on alternating days, reducing the burden on
302 each study participant.

303

304 *3.8. Clinical implications*

305 The implications of a weight loss difference of about ~1.14 after 8 weeks is likely to be
306 relatively modest, and it is not certain if this effect would persist over the longer term.
307 However, an ~20 % greater weight loss with SAAR may be an appealing implication for
308 individuals wanting to lose weight. The added possibility that RMR is maintained despite
309 greater weight loss during SAAR, is also an attractive premise for prescription of long-term
310 SAAR-induced weight loss *if* the observed RMR effect persists. Although we have shown that
311 it is possible to implement an 8-week dietary intervention with SAAR with excellent
312 adherence, its feasibility in a setting without close follow-up or full food provision is
313 unknown. Other approaches to limit intake of SAA should therefore be explored.

314

315 *3.9. Strengths and limitations*

316 This study has several strengths, including the randomized and double-blind design, and the
317 broad approach to data collection to thoroughly describe the effect of SAAR in humans. By
318 taking measures against low participant adherence, we were able to maintain a low drop-out
319 rate (10 % vs. expected 25 %) and high compliance, likely due to the close follow-up by
320 registered dietitians and provision of all foods free of charge for the duration of the

321 intervention. Good overall adherence was further indicated by the distinct differences in
322 urinary excretion of sulfate, the end-product of sulfur amino acid oxidation.

323 Several limitations should be considered; because the study was performed in free-
324 living subjects, we were unable to standardize the intake of SAA to kilogram of body weight.
325 This means that although we succeeded in comparing sharply contrasting absolute levels of
326 the SAA in the diet, intake relative to each subjects' body weight varied, which likely resulted
327 in increased variation and decreased statistical power. It is reasonable to assume that
328 adjustments for baseline body weight and within-subject correlation in the statistical models
329 handle a portion of this probable source of bias, but other impacts cannot be excluded.
330 Therefore, inpatient studies, where total control of dietary intake and protocol adherence are
331 simpler to implement, would provide more precise information on the biological effects of
332 SAAR in humans, but would do so at the expense of generalizability to the real-life situation.
333 An additional limitation with the present study includes the relatively short study duration of
334 8 weeks. Lastly, the intake of SAA in the control group may be higher than a typical Western
335 diet, however, relative to body weight the content it is in line with reported intake in upper
336 quantile groups in large population studies including NHANES and the Framingham cohort
337 studies⁶⁻⁸.

338

339

340 **4. Conclusion**

341 In conclusion, a plant-based whole food SAAR intervention for 8 weeks led to greater weight
342 loss and decreased serum leptin concentrations and increased plasma concentrations of ketone
343 bodies. In addition, SAAR affected adipose tissue gene expression related to ribosomal
344 proteins, transcription regulation and membrane components. Despite greater weight loss
345 there were no clear differences in RMR between the SAAR and control groups, indicating that
346 SAAR may maintain RMR through mechanisms that may not include typical mediators

347 identified from animal studies. It is not known whether these effects persist over the longer
348 term, and studies with a longer duration should be performed.

349

350

351 **5. Methods**

352 5.1. *Study design*

353 Details about study design, recruitment strategies, inclusion and exclusion criteria,
354 randomization, blinding, diet run-in period, dietary intervention, and measures taken to
355 increase adherence can be found in the published study protocol⁶³, with additional information
356 in the online **Supplement**.

357 Briefly, we conducted an 8-week, double-blind, randomized controlled dietary
358 intervention study at the Centre for Clinical Nutrition at the University of Oslo, Norway, from
359 March 2021 to March 2022. Healthy men and women aged 18 to 45 years, with a body mass
360 index (BMI) between 27 and 35 kg/m², were invited to participate. Of the 158 people assessed
361 for eligibility, 72 were invited to participate in the study. Sixty-one participants (45 women,
362 16 men) accepted the invitation and were randomized in blocks stratified by sex to either the
363 SAAR or the control group with 1:1 allocation ratio. Two participants were unable to start the
364 intervention due to Covid-19 (n = 1) and other illness (n = 1) related reasons, and therefore a
365 total of 59 started the intervention at baseline. All participants gave informed consent and the
366 study was conducted according to the Declaration of Helsinki. The study was approved by the
367 Regional Ethical Committee South-East (Ref no. 123644).

368 All participants performed a 7-day run-in period with instructions to follow the Nordic
369 Nutrition Recommendations⁶⁴, and to maintain their habitual physical activity. Participants
370 were instructed to fast for 12 h, and to avoid strenuous physical activity, alcohol and caffeine
371 for 24 h prior to the study visit, in accordance with the protocol for RMR measurements in the
372 whole room indirect calorimeter (WRIC).

373 To blind participants to the intervention, we developed a SAA restricted base diet that
374 was identical in both groups and consisted of vegan plant-based whole foods, as methionine
375 and cysteine are abundant in animal-derived protein and in certain fruit, grains, nuts, and
376 vegetables. In addition, the diet was supplemented with an amino acid powder drink mix

377 without methionine and cysteine (XMET XCYS Maxamaid, Nutricia Norway AS, Oslo,
378 Norway), 10 µg /d of vitamin D (Løft, Sweden) and 225 µg/d of iodine (Nycoplus, Norway)
379 to achieve adequate nutrient intakes in line with the Nordic Nutritional Recommendations⁶⁴.
380 All foods were delivered home to the participant on a weekly basis. Participants received two
381 7-day menus with detailed recipes that rotated every 2 weeks. To not place excessive
382 limitations on the participants' social life, they were allowed to replace one regular meal with
383 one *ad libitum* meal per week to increase compliance (see below). In addition, participants
384 were allowed to consume foods without SAA from a pre-specified list *ad libitum*. The mean
385 energy content of the base diet was 2401 kcal/day for men and 2030 kcal/day for women. The
386 relative contribution of total fat, carbohydrates, and protein in the SAAR base diet was
387 approximately 34 energy % (E%), 46 E% and 13 E%, respectively. The mean daily dietary
388 composition with and without an estimated *ad libitum* meal is shown in **Supplemental Table**
389 **S1**.

390 The contrasting SAA content between the SAAR and control group was adjusted with
391 capsules. The SAAR group was given 8 capsules containing a total of 3 g/day of maltodextrin,
392 whereas the control group was given 8 capsules containing a total of 1.125 g/day of
393 methionine and 2.50 g/d of cysteine, and were recommended to distribute these evenly with
394 meals. In the SAAR group, mean intake of total SAA from diet and capsules was 1.9 g/d for
395 men and 1.8 g/d for women. In the control group, mean intake of total SAA from diet and
396 capsules was 5.5 g/day for men and 5.4 g/day for women. This translated to a mean (SD)
397 intake of SAA of 19.2 (1.83) g/kg/d in SAAR and 62.1 (6.07) g/kg/d in controls. The intake of
398 SAA in the SAAR and the control groups are in line with the FAO recommended daily
399 allowance of 19 mg/kg/d⁶⁵ and the median in the upper intake quintile of SAA in the National
400 Health and Nutrition Examination Survey (NHANES) (62.7 mg/kg/d)⁶, respectively.
401 Examples of daily meals in the base diet are given in **Supplemental Table S2**.

402 To maintain participant adherence, the participants received all foods free of charge
403 delivered to their homes once weekly. Furthermore, two follow-up conversations were
404 scheduled with registered dietitians, whom they could otherwise contact at any time during
405 the study period if necessary. In addition, the allowance of one self-chosen *ad libitum* meal
406 per week was included to limit consequences for their social life. The composition of this
407 meal was recorded in a food diary.

408 Subjective compliance to the dietary interventions were recorded using food diaries
409 and evaluation forms, and the participants were required to return any capsules that were not
410 consumed. Objective markers of compliance included 24-h excretion of sulfate, methionine
411 total homocysteine (tHcy), cystathionine, and tCys. The primary outcome in the present study
412 was body weight. Because the power calculation was only done for body weight and not
413 secondary outcomes, the other outcomes were regarded as exploratory. The latter outcomes
414 included SAA profile in plasma (methionine, tHcy, cystathionine, and tCys) and 24-h urine
415 (with the addition of sulfate); fat mass (total, arm, leg, trunk, gynoid, android, visceral and
416 subcutaneous); fat free mass; RMR and its components (respiratory quotient [RQ], fat
417 oxidation, glucose oxidation); adipose tissue gene expression profiles; blood biomarkers
418 related to metabolic health (total cholesterol, low-density cholesterol, high-density
419 cholesterol, apolipoprotein B, apolipoprotein A1, triglycerides, insulin, glucose, C-peptide);
420 endocrine factors (FGF-21, IGF-1, adiponectin, leptin, thyroid-stimulating hormone, Free T4,
421 insulin, C-peptide, gastric inhibitory peptide-1, glucagon-like protein-1, peptide YY,
422 pancreatic peptide, ghrelin); plasma ketone bodies (β -hydroxybutyrate, acetoacetate, acetone,
423 acetate); and other/safety markers (vitamin B12, methylmalonic acid, creatinine, urea, alanine
424 aminotransferase [ALAT] and aspartate aminotransferase [ASAT]). Details of outcome
425 assessment are given below and in the online **Supplement**. All outcomes were measured at
426 baseline, 4 and 8 weeks, except for IGF-1 and adiponectin (baseline and 8 weeks).

427

428 *5.2. Anthropometry and body composition*

429 Body anthropometry (waist and hip circumference, height and weight) were measured
430 according to standardized operating procedures with the participant wearing light clothing.
431 Waist and hip circumference were measured thrice and the average was used. Standing height
432 and weight were measured once using the electronic height board (SECA 285, SECA,
433 Germany). All measurements were recorded with one decimal. Body composition was
434 measured by the Dual-energy X-ray absorptiometry (DXA) procedure (Lunar iDXA, GE
435 Healthcare Lunar, Buckinghamshire, United Kingdom). The software enCORE™ version 18
436 was used for data acquisition. DXA scans were performed on fasting subjects using
437 standardized procedures adapted from the International Society for Clinical Densitometry⁶⁶.

438

439 *5.3. Blood pressure measurements*

440 Blood pressure was measured using a CARESCAPE V100 Vital Signs Monitor (GE
441 Healthcare, Chicago, Illinois, USA) with the participant in a seated position and the average
442 of three readings was used.

443

444 *5.4. Whole-room indirect calorimetry*

445 Resting metabolic rate (RMR; kcal/d), macro-nutrient oxidation (g/d) and the RQ [liters (V)
446 of carbon dioxide (CO₂)/liters of oxygen (O₂)] were measured using a whole-room indirect
447 calorimeter (WRIC) specific for RMR. This involved the determination of O₂ (%), CO₂ (%)
448 and water vapor pressure (WVP, kPa) according to previously published protocols^{67,68}.

449 After arriving to the research center in the morning, subjects urinated and were placed
450 inside the RMR-WRIC in a comfortable recliner for 60 minutes. They were instructed to

451 remain seated, minimize movements and keep the lights on. To prevent subjects from falling
452 asleep, they were encouraged to bring a book or an iPad to watch TV.

453 Metabolic rate (kcal/min) was calculated using Weir's equation⁶⁹ along with the RQ,
454 fat oxidation and glucose oxidation. Substrate oxidation was calculated as published
455 previously⁷⁰. Mean RMR (kcal/min), fat oxidation (g/min) and glucose oxidation (g/min)
456 were multiplied by 1440 to convert to kcal/day or g/day. The WRIC measurements have been
457 validated against 10 propane combustion tests⁶⁷ with a mean (SD) error of -1.3 (1.1) % for
458 RMR and -1.4 (0.5) % for RQ and repeated measurements in 19 eligible subjects with a
459 within-person coefficient of variation of 2.68 %⁷¹.

460

461 *5.5. Blood samples*

462 Fasting venous blood samples were collected at each study visit, and included one 4 mL
463 EDTA-lined vacuum tube, one lithium-heparin 5 mL tube, and one serum gel 5 mL for
464 immediate analyses of routine markers. One additional lithium-heparin 5 mL tube for amino
465 acid assays including methionine, tHcy, cystathionine, and tCys was collected. One additional
466 5 mL serum gel tube was collected for analysis of adipokines and hepatokines.

467 All samples were inverted 6-8 times directly after withdrawal. For immediate analyses of
468 routine markers, the 4 mL EDTA tube was stored at 4 °C whereas the 5 mL lithium-heparin
469 tube was centrifuged at 2500 g at 4 °C for 10 min, and stored at 4 °C. The 5 mL serum tubes
470 were left in room temperature for a minimum of 30 min to ensure clot activation and then
471 centrifuged for 10 min at 1500 g. Serum was stored at -20 °C until analysis of routine
472 markers. For amino acid assays, one 5 mL lithium-heparin tube for amino acid assays was
473 directly placed in ice water, and centrifuged within 15 min at 2000 g at 4 °C for 5 min.
474 Immediately after centrifugation, a minimum of 650 µl were transferred to cryotubes and
475 stored at -80 °C until analysis. Amino acid assays were performed at the Department of

476 Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University
477 and General University Hospital in Prague. The samples were shipped on dry ice.

478

479 *5.6. Urine samples*

480 A 24-h urine collection took place before each study visit and started after the participants had
481 emptied their bladder for the first time the morning prior. All urine after this point was
482 collected in 3 L containers with light protection and stored at 4°C. Twenty-four-hour urine
483 were subsequently aliquoted and stored at – 80°C until analysis, and shipped on dry ice to
484 Prague.

485

486 *5.7. Biochemical analyses*

487 Sulfur-containing compounds except sulfate were quantified as described elsewhere ⁷².
488 Briefly, tCys and tHcy were assayed by high-performance liquid chromatography after
489 reduction with Tris(2-carboxyethyl)phosphine and derivatization with 7-fluorobenzo-2-oxa-
490 1,3-diazole-4-sulfonate while methionine and cystathionine were assayed by liquid
491 chromatography tandem mass spectrometry using a commercial kit from Phenomenex. Sulfate
492 in urine was determined by a newly developed method (Barvíková et al, unpublished) as
493 follows: samples of urine were diluted 100-times with deionized water, calibration standards
494 of sulfate (0-20 mg/L) were prepared by diluting the Multi Anion Standard (certified
495 TraceCERT®, Sigma Aldrich) with deionized water. Inorganic anions were separated on
496 Shodex IC-90 4E column (Showa Denko Europe GmbH, Munich, Germany) with isocratic
497 elution (1.8mM sodium carbonate and 1.7mM sodium bicarbonate) using Ion Exchange
498 Chromatograph with suppressor from Shimadzu (Shimadzu Europa GmbH). Pumps SIL-20Ai
499 and autosampler SIL-20AC were coupled with CDD-10A conductivity detector, the system
500 was coupled with the ion suppressor Xenoic ® Asurex-A200 (Xenoic ® Asurex-AR1

501 cartridge, Diduco AB, Umeå, Sweden). Urinary sulfate concentration was calculated from
502 calibration curves, converted to mM and expressed as mmol/24 h. All other urinary
503 metabolites were expressed as $\mu\text{mol}/24\text{ h}$.

504 Routine clinical biomarkers (ASAT, ALAT; creatinine (serum and urine), urea,
505 glucose, insulin, c-peptide, total cholesterol, LDL, HDL, apolipoprotein B and apolipoprotein
506 A1, vitamin B12 and methylmalonic acid) were measured at the Department of Medical
507 Biochemistry (Oslo University Hospital Rikshospitalet, Oslo, Norway) by colorimetric and/or
508 enzymatic methods (Cobas c702 analyzer, Roche Diagnostics International Ltd, Rotkreuz,
509 Switzerland).

510 Serum concentrations of FGF-21, gastric inhibitory peptide-1, glucagon-like peptide-
511 1, ghrelin, pancreatic peptide, peptide YY and leptin (MSD U-Plex Metabolic Group 1
512 (Human) - Multiplex Assays Kit Cat No: K151ACL-1), IGF-1 (R&D Systems Human IGF-1
513 Quantikine ELISA Kit Cat No: DG100B), and adiponectin (MSD R-Plex Human Adiponectin
514 Assay Kit Cat no: K151YTR-2) were measured at AS VITAS using a multiplexed ELISA
515 platform.

516 Plasma β -hydroxybutyrate, acetoacetate, acetone and acetate were measured using a
517 commercial high-throughput proton NMR metabolomics platform (Nightingale Health Ltd.
518 Helsinki, Fin) as described previously⁷³.

519

520 *5.8. Adipose tissue biopsies*

521 WAT biopsies were available from the first and last study visit and was taken from the
522 periumbilical region. The skin was sterilized, and the skin and subcutis were anaesthetized by
523 injecting 5 mL of a local anesthetic (Xylocaine 10 mg/mL AstraZeneca, Södertälje, Sweden).
524 Subcutaneous WAT were immediately dissected on an ice-cold aluminum plate to remove

525 blood and other materials before aliquots were snap-frozen in 1.5 mL cryotubes and stored at
526 – 80 °C until analysis.

527

528 *5.9. RNA isolation*

529 WAT RNA was isolated using a modified version of the protocol provided by manufacturer
530 (Nucleospin RNA, Mini kit for RNA purification, Macherey-Nagel, Germany). Briefly,
531 approximately 100 mg tissue was homogenized using 750 µl Triazol and centrifuged at
532 12 000 RCF for 15 minutes at 4 °C. Then, 0.3 ml chloroform was added to the sample prior to
533 another centrifugation step at 12 000 RCF for at 15 minutes at 4 °C. RNA-containing aqueous
534 phase was extracted and mixed with 96 % EtOH at room temperature. The subsequent steps
535 followed the manufacturer protocol. RNA integrity was measured by the RNA 6000 Nano Kit
536 and an RNA integrity number of > 7 was considered sufficient quality.

537

538 *5.10. mRNA sequencing and bioinformatics*

539 Fifty-one participants had full sets of WAT that were sent to the Norwegian Sequencing
540 Centre (www.sequencing.uio.no) for analysis.

541 Libraries were prepared with the Illumina TrueSeq stranded mRNA kit using 500 ng
542 input per sample, following the manufacturer's protocol. Sequencing was performed on an
543 Illumina NovaSeq over two quarters of an S4 flow cell with the XP workflow and 151 bp
544 paired end reads, according to manufacturer's instructions. Base calling was performed with
545 RTA v3.4.4, and demultiplexing with bcl2fastq v2.20.0.422. Reads quality filtering were
546 performed using BBMap v38.79-GCC-8.3.0. Read T overhang was filtered by removing the
547 151st base on each read, resulting in 150 bp reads, followed by filtering of adaptor sequences.
548 Read alignment was performed using the ultra-sensitive spliced-aware aligner STAR v2.7.9a-
549 GCC-11.2.0⁷⁴ and pseudo-alignment was performed using Kallisto v0.46.1, both against the

550 GENCODE human genome release 41(GRCh38.p13) primary assembly, including the
551 corresponding annotation file. The union-exon based approach was used for gene
552 quantification using STAR⁷⁵ and the resulting gene counts were normalized using the
553 trimmed mean of the M-values (TMM) algorithm. Transcript level quantification using
554 Kallisto was normalized as transcripts per million (TPM). Subsequent batch correction (a
555 subset of samples was re-sequenced in a separate run) was done using the `removeBatchEffect`
556 function in edgeR v3.38.4⁷⁶. Down-stream gene level differential expression analysis was
557 performed using DESeq2 v1.38.2, and transcript level differential expression analysis was
558 performed using Sleuth v30.1. P-values were corrected for multiple testing using the
559 Benjamini-Hochberg method for controlling the false discovery rate (FDR) at 5 %⁷⁷. GAGE
560 was performed using the GAGE v2.44.0 R package for global analyses of regulated pathways.
561 The default native workflow was followed as recommended for mRNA sequencing data⁷⁸.

562

563 *5.11. Sample size calculations*

564 Sample size calculations have been described in the previously published protocol⁶³. Briefly,
565 we hypothesized a -1 kg difference after 4 weeks and -3 kg difference in body weight after 8
566 weeks between the SAAR group and controls. We hypothesized a correlation of 0.9 for body
567 weight between study visits and a decay rate of 0.5. The online tool GLIMPSE was used for
568 power calculations (<https://v2.glimpse.samplesizeshop.org>). The estimated sample size was
569 46, and accounting for 25 % drop-out ($46/1 - 0.25$) the final number was 61.

570

571 *5.12. Statistical analyses*

572 Continuous and categorical variables are presented descriptively as mean (SD) and median
573 (interquartile range [IQR]), and n (%), respectively. No significance test for group differences
574 in participant characteristics (**Table 1**) have been performed in accordance with CONSORT

575 guidelines⁷⁹. As specified in the protocol⁶³, blinded outcome analyses were performed by
576 using linear mixed model regression, which is robust to missing values. To correct for any
577 baseline differences, we used the constrained approach as described by Coffman *et al.*⁸⁰ and
578 Twisk⁸¹. This approach increases precision by forcing baseline values of the outcome to be
579 equal between groups. Thus, the model included the visit covariate, interaction terms for visit
580 and the grouping covariate at 4 weeks and 8 weeks, the stratification variable sex, and a
581 random intercept to control for within-subject correlation. This type of baseline adjustment
582 was performed for all outcome models. The resulting p-values from the interaction terms
583 indicate the difference between groups at each visit (4 weeks and 8 weeks). Unless otherwise
584 specified, model output is presented as β and 95 % CIs. EMMs and corresponding 95 % CIs
585 derived from the models are presented in the online supplement together with the observed
586 values at each timepoint. The main analyses were performed on the ITT population, but PP
587 analyses (in which drop-outs are excluded) are presented in the online supplement. Because
588 we were interested in the direct effect of the diet on body composition independently of total
589 mass loss, additional models for body composition outcomes were created with adjustment for
590 total weight loss. In models with RMR as the outcome, models were adjusted for fat free
591 mass. The assumption of normally distributed model residuals was inspected visually. In
592 initial analyses, residuals for β -hydroxybutyrate, acetoacetate and FGF-21 were severely
593 skewed, and these markers were therefore log-transformed before analysis. A p-value < 0.05
594 was considered statistically significant. Considering that we did not power the trial for
595 secondary outcomes, all other outcomes are regarded as exploratory and no multiplicity
596 adjustments were performed. All statistical analyses and plots were performed/made in R
597 version 4.2.1 in the R Studio IDE version 2022.02.3 Build 492, using packages in the
598 *tidyverse*, *lmerTest* and *stats*.

599

600

601 **6. Data availability**

602 Raw data from this study cannot be made publicly available due to existing European privacy
603 regulations. Requests for data can be made to the corresponding author and will be shared
604 pending approved protocols by relevant ethical committees and privacy regulation authorities.

605

606 **7. Author contributions**

607 TO, HR, KJV and KR contributed to study design; BØ developed and designed the base diet
608 for the intervention; TO, ES, HJ, BD, AADV, AFD KS and KJV collected data; ES: had main
609 responsibility for supervision of study participants; TO, ET, SL and MT performed statistical
610 analyses; KB and VK were responsible for biochemical analyses of sulfur amino acids and
611 sulfate; RR developed the protocol for calorimetry measurements and data analysis of raw
612 calorimetry data; AE and MvG contributed intellectually; TO, ES and KJV drafted the
613 manuscript; All authors revised the draft and approved the final version of the manuscript.

614

615 **Conflicts of interest**

616 None declared

617 **8. Acknowledgements**

618 We wish to thank Elin Augestad for assistance with blood sampling; Elisabeth Andrea
619 Johnsen and Stine Sofie Strømmland for assistance with sample handling; and chef Johannes
620 Grødal for developing meals for the dietary intervention. Finally, we wish to thank all study
621 subjects for their time. This project has received funding from The Research Council of
622 Norway (Grant no: 310475) under the umbrella of the European Joint Programming Initiative
623 “A Healthy Diet for a Healthy Life” (JPI HDHL) and of the ERA-NET Cofund HDHL
624 INTIMIC (GA N° 727565 of the EU Horizon 2020 Research and Innovation Programme),
625 and Institute of Basic Medical Sciences, University of Oslo, and Henning och Johan Throne-
626 Holsts stiftelse. VK and KB were supported by the Czech Ministry of Education, Sports and
627 Youth (STAY 8F20013), institutional support was provided by Charles University (program
628 COOPERATIO-Metabolic Disorders) and Ministry of Health DRO VFN64165.

629

630

631

632 9. References

- 633 1. Protein and amino acid requirements in human nutrition □ : report of a joint
634 FAO/WHO/UNU expert consultation. <https://apps.who.int/iris/handle/10665/43411>.
- 635 2. El-Khairi, L., Ueland, P. M., Nygard, O., Refsum, H. & Vollset, S. E. Lifestyle and
636 cardiovascular disease risk factors as determinants of total cysteine in plasma: the
637 Hordaland Homocysteine Study. *Am J Clin Nutr* **70**, 1016–1024 (1999).
- 638 3. Elshorbagy, A. K. *et al.* Homocysteine, cysteine, and body composition in the
639 Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism?
640 *Am J Clin Nutr* **88**, 738–746 (2008).
- 641 4. Elshorbagy, A. K. *et al.* The association of fasting plasma sulfur-containing compounds
642 with BMI, serum lipids and apolipoproteins. *Nutr Metab Cardiovasc Dis* **22**, 1031–
643 1038 (2012).
- 644 5. Elshorbagy, A. K., Refsum, H., Smith, A. D. & Graham, I. M. The association of
645 plasma cysteine and gamma-glutamyltransferase with BMI and obesity. *Obesity (Silver*
646 *Spring)* **17**, 1435–1440 (2009).
- 647 6. Dong, Z. *et al.* Association of sulfur amino acid consumption with cardiometabolic risk
648 factors: Cross-sectional findings from NHANES III. *EClinicalMedicine* vol. 19 (2020).
- 649 7. Dong, Z. *et al.* Association of dietary sulfur amino acid intake with mortality from
650 diabetes and other causes. *Eur J Nutr* **61**, 289–298 (2022).
- 651 8. Dong, Z. *et al.* Cumulative Consumption of Sulfur Amino Acids and Risk of Diabetes:
652 a Prospective Cohort Study. *J Nutr* (2022).
- 653 9. Tore, E. C. *et al.* Associations between plasma sulfur amino acids and specific fat
654 depots in two independent cohorts: CODAM and The Maastricht Study. *Eur J Nutr*
655 (2022) doi:10.1007/s00394-022-03041-4.
- 656 10. Elshorbagy, A. K., Turner, C., Bastani, · Nasser, Refsum, H. & Kwok, T. The
657 association of serum sulfur amino acids and related metabolites with incident diabetes:
658 a prospective cohort study. *European Journal of Nutrition* 2022 1–13 (2022)
659 doi:10.1007/S00394-022-02872-5.
- 660 11. Orentreich, N., Matias, J. R., DeFelice, A. & Zimmerman, J. A. Low methionine
661 ingestion by rats extends life span. *Journal of Nutrition* **123**, 269–274 (1993).
- 662 12. Malloy, V. L. *et al.* Methionine restriction decreases visceral fat mass and preserves
663 insulin action in aging male Fischer 344 rats independent of energy restriction. *Aging*
664 *Cell* **5**, 305–314 (2006).
- 665 13. Malloy, V. L. *et al.* Methionine restriction prevents the progression of hepatic steatosis
666 in leptin-deficient obese mice. *Metabolism* **62**, 1651–61 (2013).
- 667 14. Hasek, B. E. *et al.* Dietary methionine restriction enhances metabolic flexibility and
668 increases uncoupled respiration in both fed and fasted states. *Am J Physiol Regul Integr*
669 *Comp Physiol* **299**, 728–739 (2010).
- 670 15. Perrone, C. E., Mattocks, D. A., Jarvis-Morar, M., Plummer, J. D. & Orentreich, N.
671 Methionine restriction effects on mitochondrial biogenesis and aerobic capacity in
672 white adipose tissue, liver, and skeletal muscle of F344 rats. *Metabolism* **59**, 1000–
673 1011 (2010).
- 674 16. Perrone, C. E. *et al.* Methionine restriction effects on 11β-HSD1 activity and
675 lipogenic/lipolytic balance in F344 rat adipose tissue. *J Lipid Res* **49**, 12–23 (2008).
- 676 17. Hasek, B. E. *et al.* Remodeling the integration of lipid metabolism between liver and
677 adipose tissue by dietary methionine restriction in rats. *Diabetes* **62**, 3362–3372 (2013).
- 678 18. Fang, H., Stone, K. P., Wanders, D., Forney, L. A. & Gettys, T. W. The Origins,
679 Evolution, and Future of Dietary Methionine Restriction. *Annual Reviews of Nutrition*
680 (2022).

- 681 19. Stone, K. P., Wanders, D., Orgeron, M., Cortez, C. C. & Gettys, T. W. Mechanisms of
682 increased in vivo insulin sensitivity by dietary methionine restriction in mice. *Diabetes*
683 **63**, 3721–3733 (2014).
- 684 20. Ables, G. P. & Johnson, J. E. Pleiotropic responses to methionine restriction. *Exp*
685 *Gerontol* **94**, 83–88 (2017).
- 686 21. Johnson, J. E. & Johnson, F. B. Methionine Restriction Activates the Retrograde
687 Response and Confers Both Stress Tolerance and Lifespan Extension to Yeast, Mouse
688 and Human Cells. *PLoS One* **9**, e97729 (2014).
- 689 22. Nichenametla, S. N., Mattocks, D. A. L. & Malloy, V. L. Age-at-onset-dependent
690 effects of sulfur amino acid restriction on markers of growth and stress in male F344
691 rats. *Aging Cell* **19**, e13177 (2020).
- 692 23. Cooke, D. *et al.* Weight Loss and Concomitant Adipose Autophagy in Methionine-
693 Restricted Obese Mice is Not Dependent on Adiponectin or FGF21. *Obesity (Silver*
694 *Spring)* (2020).
- 695 24. Plummer, J. D., Johnson, J. E. & Jay Johnson, C. E. Intermittent methionine restriction
696 reduces IGF-1 levels and produces similar healthspan benefits to continuous
697 methionine restriction. *Aging Cell* **00**, e13629 (2022).
- 698 25. Hill, C. M. *et al.* FGF21 Signals Protein Status to the Brain and Adaptively Regulates
699 Food Choice and Metabolism. *Cell Rep* **27**, 2934-2947.e3 (2019).
- 700 26. Wanders, D. *et al.* FGF21 mediates the thermogenic and insulin-sensitizing effects of
701 dietary methionine restriction but not its effects on hepatic lipid metabolism. *Diabetes*
702 **66**, 858–867 (2017).
- 703 27. Brown-Borg, H. M. *et al.* Growth hormone signaling is necessary for lifespan
704 extension by dietary methionine. *Aging Cell* **13**, 1019–1027 (2014).
- 705 28. Brown-Borg, H. M., Rakoczy, S., Wonderlich, J. A., Borg, K. E. & Rojanathammanee,
706 L. Metabolic adaptation of short-living growth hormone transgenic mice to methionine
707 restriction and supplementation. *Ann N Y Acad Sci* **1418**, 118–136 (2018).
- 708 29. Richie, J. P. *et al.* Dietary Methionine and Total Sulfur Amino Acid Restriction in
709 Healthy Adults. *J Nutr Health Aging* **27**, (2023).
- 710 30. Plaisance, E. P. *et al.* Dietary methionine restriction increases fat oxidation in obese
711 adults with metabolic syndrome. *Journal of Clinical Endocrinology and Metabolism*
712 **96**, 836–840 (2011).
- 713 31. Olsen, T. *et al.* Effects of dietary methionine and cysteine restriction on plasma
714 biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in
715 women with overweight or obesity: A double-blind randomized controlled pilot study.
716 *J Transl Med* **18**, 122 (2020).
- 717 32. Olsen, T. *et al.* Combining dietary sulfur amino acid restriction with polyunsaturated
718 fatty acid intake in humans: A randomized controlled pilot trial. *Nutrients* **10**, (2018).
- 719 33. Plaisance, E. P. *et al.* Dietary methionine restriction increases fat oxidation in obese
720 adults with metabolic syndrome. *Journal of Clinical Endocrinology and Metabolism*
721 **96**, 836–840 (2011).
- 722 34. Kahleova, H. *et al.* Effect of a Low-Fat Vegan Diet on Body Weight, Insulin
723 Sensitivity, Postprandial Metabolism, and Intramyocellular and Hepatocellular Lipid
724 Levels in Overweight Adults: A Randomized Clinical Trial. *JAMA Netw Open* **3**,
725 e2025454–e2025454 (2020).
- 726 35. Wanders, D. *et al.* UCP1 is an essential mediator of the effects of methionine
727 restriction on energy balance but not insulin sensitivity. *FASEB Journal* **29**, 2603–2615
728 (2015).

- 729 36. Ghosh, S., Forney, L. A., Wanders, D., Stone, K. P. & Gettys, T. W. An integrative
730 analysis of tissue-specific transcriptomic and metabolomic responses to short-term
731 dietary methionine restriction in mice. *PLoS One* **12**, 1–22 (2017).
- 732 37. Ravussin, E., Smith, S. R. & Ferrante, A. W. Physiology of Energy Expenditure in the
733 Weight-Reduced State. *Obesity* **29**, (2021).
- 734 38. Müller, M. J., Geisler, C., Heymsfield, S. B. & Bosy-Westphal, A. Recent advances in
735 understanding body weight homeostasis in humans. *FI000Res* **7**, 1025 (2018).
- 736 39. Ables, G. P. *et al.* Dietary Methionine Restriction in Mice Elicits an Adaptive
737 Cardiovascular Response to Hyperhomocysteinemia. *Scientific Reports 2015 5:1* **5**, 1–
738 10 (2015).
- 739 40. Elshorbagy, A. K. *et al.* Sulfur amino acids in methionine-restricted rats:
740 hyperhomocysteinemia. *Nutrition* **26**, 1201–1204 (2010).
- 741 41. Olsen, T. *et al.* Combining dietary sulfur amino acid restriction with polyunsaturated
742 fatty acid intake in humans: A randomized controlled pilot trial. *Nutrients* **10**, (2018).
- 743 42. Olsen, T. *et al.* Effects of dietary methionine and cysteine restriction on plasma
744 biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in
745 women with overweight or obesity: A double-blind randomized controlled pilot study.
746 *J Transl Med* **18**, 122 (2020).
- 747 43. Guttormsen, A. B., Solheim, E. & Refsum, H. Variation in plasma cystathionine and its
748 relation to changes in plasma concentrations of homocysteine and methionine in
749 healthy subjects during a 24-h observation period. *American Journal of Clinical*
750 *Nutrition* **79**, (2004).
- 751 44. Tore, E. C. *et al.* The Associations of Habitual Intake of Sulfur Amino Acids, Proteins
752 and Diet Quality with Plasma Sulfur Amino Acid Concentrations: The Maastricht
753 Study. *J Nutr* **153**, 2027–2040 (2023).
- 754 45. Stipanuk, M. H. & Ueki, I. Dealing with methionine/homocysteine sulfur: Cysteine
755 metabolism to taurine and inorganic sulfur. *J Inherit Metab Dis* **34**, 17–32 (2011).
- 756 46. Stipanuk, M. H., Ueki, I., Dominy Jr., J. E., Simmons, C. R. & Hirschberger, L. L.
757 Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. *Amino*
758 *Acids* **37**, 55–63 (2009).
- 759 47. Sikalidis, A. K. *et al.* Upregulation of capacity for glutathione synthesis in response to
760 amino acid deprivation: regulation of glutamate-cysteine ligase subunits. *Amino Acids*
761 **46**, 1285–1296 (2014).
- 762 48. Krist, J. *et al.* Effects of Weight Loss and Exercise on Apelin Serum Concentrations
763 and Adipose Tissue Expression in Human Obesity. *Obes Facts* **6**, 57–69 (2013).
- 764 49. Janke, J. *et al.* Adipose tissue and circulating endothelial cell specific molecule-1 in
765 human obesity. *Horm Metab Res* **38**, 28–33 (2006).
- 766 50. Nichenametla, S. N., Mattocks, D. A. L., Malloy, V. L. & Pinto, J. T. Sulfur amino
767 acid restriction-induced changes in redox-sensitive proteins are associated with slow
768 protein synthesis rates. *Ann N Y Acad Sci* **1418**, 80–94 (2018).
- 769 51. Jonsson, W. O. *et al.* Kinetic proteomics identifies targeted changes in liver
770 metabolism and the ribo-interactome by dietary sulfur amino acid restriction.
771 *Geroscience* 1–17 (2023).
- 772 52. Cooke, D. *et al.* Weight Loss and Concomitant Adipose Autophagy in Methionine-
773 Restricted Obese Mice is Not Dependent on Adiponectin or FGF21. *Obesity (Silver*
774 *Spring)* **28**, 1075–1085 (2020).
- 775 53. Varady, K. A. Intermittent versus daily calorie restriction: which diet regimen is more
776 effective for weight loss? *Obes Rev* **12**, (2011).

- 777 54. Fang, H., Stone, K. P., Forney, L. A., Wanders, D. & Gettys, T. W. Nutritional
778 Regulation of Hepatic FGF21 by Dietary Restriction of Methionine. *Front Endocrinol*
779 (*Lausanne*) **12**, 1629 (2021).
- 780 55. Miller, R. A. *et al.* Methionine-deficient diet extends mouse lifespan, slows immune
781 and lens aging, alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte
782 MIF levels and stress resistance. *Aging Cell* **4**, 119–125 (2005).
- 783 56. Nichenametla, S. N. *et al.* Cysteine restriction □ specific effects of sulfur amino acid
784 restriction on lipid metabolism. *Aging Cell* (2022).
- 785 57. Elshorbagy, A. K. *et al.* Cysteine supplementation reverses methionine restriction
786 effects on rat adiposity: significance of stearyl-coenzyme A desaturase. *J Lipid Res*
787 **52**, 104–112 (2011).
- 788 58. Castano-Martinez, T. *et al.* Methionine restriction prevents onset of type 2 diabetes in
789 NZO mice. *FASEB J* **33**, 7092–7102 (2019).
- 790 59. Fontana, L., Weiss, E. P., Villareal, D. T., Klein, S. & Holloszy, J. O. Long-term
791 effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in
792 humans. *Aging Cell* **7**, 681 (2008).
- 793 60. Belobrajdic, D. P. *et al.* Moderate energy restriction-induced weight loss affects
794 circulating IGF levels independent of dietary composition. *Eur J Endocrinol* **162**,
795 1075–1082 (2010).
- 796 61. Telgenkamp, I. *et al.* Contribution of Liver Fat to Weight Loss-Induced Changes in
797 Serum Hepatokines: A Randomized Controlled Trial. *J Clin Endocrinol Metab* **104**,
798 2719–2727 (2019).
- 799 62. Fontana, L. *et al.* Effects of 2 □ year calorie restriction on circulating levels of IGF □ 1,
800 IGF □ binding proteins and cortisol in nonobese men and women: a randomized clinical
801 trial. *Aging Cell* **15**, 22 (2016).
- 802 63. Stolt, E. *et al.* Sulfur amino acid restriction, energy metabolism and obesity: a study
803 protocol of an 8-week randomized controlled dietary intervention with whole foods and
804 amino acid supplements. *J Transl Med* **19**, 153 (2021).
- 805 64. *Nordic Nutrition Recommendations 2012: Integrating nutrition and physical activity.*
806 (Nordic Council of Ministers, 2012).
- 807 65. *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids,*
808 *Cholesterol, Protein, and Amino Acids (Macronutrients). Dietary Reference Intakes for*
809 *Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids*
810 *(Macronutrients)* (2005).
- 811 66. Hangartner, T. N., Warner, S., Braillon, P., Jankowski, L. & Shepherd, J. The Official
812 Positions of the International Society for Clinical Densitometry: Acquisition of Dual-
813 Energy X-Ray Absorptiometry Body Composition and Considerations Regarding
814 Analysis and Repeatability of Measures. *Journal of Clinical Densitometry* **16**, 520–536
815 (2013).
- 816 67. Rising, R., Foerster, T., Arad, A. D., Albu, J. & Pi-Sunyer, X. Validation of whole
817 room indirect calorimeters: refinement of current methodologies. *Physiol Rep* **5**,
818 e13521 (2017).
- 819 68. Rising, R., Whyte, K., Albu, J. & Pi-Sunyer, X. Evaluation of a new whole room
820 indirect calorimeter specific for measurement of resting metabolic rate. *Nutr Metab*
821 (*Lond*) **12**, 46 (2015).
- 822 69. Weir, J. B. de v. New methods for calculating metabolic rate with special reference to
823 protein metabolism. *J Physiol* **109**, 1–9 (1949).
- 824 70. Kelly, L. P. & Basset, F. A. Acute Normobaric Hypoxia Increases Post-exercise Lipid
825 Oxidation in Healthy Males. *Front Physiol* **8**, (2017).

- 826 71. Henriksen, H. B. *et al.* Validity and reproducibility of a whole-room indirect
827 calorimeter for the estimation of VO₂, VCO₂, and resting metabolic rate. *Physiol Rep*
828 **11**, (2023).
- 829 72. Kožich, V. *et al.* Human ultrarare genetic disorders of sulfur metabolism demonstrate
830 redundancies in H₂S homeostasis. *Redox Biol* **58**, (2022).
- 831 73. Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum
832 nuclear magnetic resonance metabolomics in cardiovascular epidemiology and
833 genetics. *Circ Cardiovasc Genet* **8**, 192–206 (2015).
- 834 74. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15
835 (2013).
- 836 75. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-
837 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 838 76. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential
839 expression analysis of RNA-seq data. *Genome Biol* **11**, (2010).
- 840 77. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
841 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series*
842 *B (Methodological)* **57**, 289–300 (1995).
- 843 78. Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D. & Woolf, P. J. GAGE:
844 generally applicable gene set enrichment for pathway analysis. *BMC Bioinformatics*
845 **10**, (2009).
- 846 79. Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: Updated
847 guidelines for reporting parallel group randomised trials. *J Pharmacol Pharmacother* **1**,
848 100–107 (2010).
- 849 80. Coffman, C. J., Edelman, D. & Woolson, R. F. To condition or not condition?
850 Analysing ‘change’ in longitudinal randomised controlled trials. *BMJ Open* **6**, e013096
851 (2016).
- 852 81. Twisk, J. W. R. Analysis of RCT Data with More Than One Follow-Up Measurement.
853 *Analysis of Data from Randomized Controlled Trials* 15–47 (2021).
854
855

856 **Figure legends**

857

858 **Figure 1.** A) Simplified study overview (see full CONSORT diagram in Supplemental Figure
859 S1; Effects of SAAR on B) urinary sulfate excretion; C) Change in body weight and body fat;
860 D) resting metabolic rate (RMR), carbohydrate oxidation, fat oxidation and respiratory
861 quotient (RQ); E) serum levels of fibroblast growth factor-21 (FGF-21), leptin, insulin-like
862 growth factor-1 (IGF-1) and adiponectin; F) serum β -hydroxybutyrate, acetoacetate, acetone
863 and acetate. Values are β (standard error) derived from linear mixed models with the group,
864 visit and their interaction term (group \times time) at 4 and 8 weeks as predictors. The models
865 were adjusted for baseline levels of the outcome and the randomization variable sex. Models
866 with RMR were additionally adjusted for total fat mass. The p-value denotes the difference at
867 8 weeks. ** data were available for IGF-1 and Adiponectin one baseline and the final visit
868 only.

869

870 **Figure 2.** Effects of SAAR on A) sulfur amino acid excretion in 24 h urine and B) change in
871 plasma sulfur amino acids. The models were adjusted for baseline levels of the outcome and
872 the randomization variable sex. The p-value denotes the difference at 8 weeks. Abbreviations:
873 SAAR, sulfur amino acid restriction; tCys, total cysteine; tHcy, total homocysteine. The p-
874 value indicates difference between groups after 8 weeks

875

876 **Figure 3.** A) Effects of SAAR on adipose tissue gene expression in n = 51 men and women
877 that completed the dietary intervention. Red points indicate negative changes, blue points
878 indicate positive changes. Vertical dashed lines at log₂ fold-change of -0.5 and 0.5.
879 Horizontal dashed line indicates FDR of 5 %. Data were available at baseline and after 8
880 weeks. B) shows the top 10 upregulated gene ontologies and C) shows the top 10
881 downregulated gene ontologies. Vertical dashed lines denote FDR 25 % and 5 %.

Characteristics	SAAR (n = 31)		Controls (n = 28)	
	8 (25.8)		8 (28.6)	
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)
Males, n (%)				
Age, y	33.2 (5.86)	32 (29.5, 37.0)	34.4 (6.26)	34 (29.5, 38.8)
Body weight, kg	94.4 (10.7)	93.2 (86.6, 102)	88.7 (9.22)	88.6 (82.0, 95.7)
Body mass index, kg/m ²	31.4 (2.12)	31.2 (29.5, 33.2)	30.8 (2.20)	30.3 (29.0, 32.4)
Waist-to-hip ratio	0.85 (0.08)	0.84 (0.79, 0.90)	0.86 (0.08)	0.84 (0.79, 0.92)
Percent body fat, %	42.0 (6.76)	44.0 (37.8, 47.3)	42.4 (5.80)	44.1 (39.2, 46.4)
Systolic blood pressure, mm/Hg	120 (10.9)	119 (111, 128)	119 (10.7)	118 (112, 125)
Diastolic blood pressure, mm/Hg	69.1 (7.57)	70.0 (64.0, 73.0)	70.0 (8.50)	66.7 (63.6, 76.1)
Apolipoprotein B, g/L	0.81 (0.20)	0.80 (0.65, 0.90)	0.91 (0.24)	0.90 (0.8, 1.00)
Apolipoprotein A1, g/L	1.49 (0.24)	1.50 (1.3, 1.6)	1.47 (0.26)	1.40 (1.30, 1.55)
LDL, mmol/L	2.81 (0.69)	2.80 (2.15, 3.35)	3.11 (0.71)	3.20 (2.65, 3.50)
HDL, mmol/L	1.40 (0.36)	1.30 (1.10, 1.65)	1.39 (0.38)	1.3 (1.15, 1.50)
Total cholesterol, mmol/L	4.66 (0.75)	4.90 (4.00, 5.15)	4.93 (0.83)	5.00 (4.35, 5.35)
Triglycerides, mmol/L	1.15 (0.55)	1.00 (0.7, 1.3)	1.07 (0.42)	1.00 (0.8, 1.35)
Glucose, mmol/L	5.16 (0.41)	5.20 (4.90, 5.45)	5.31 (0.50)	5.4 (5.05, 5.60)
Insulin, pmol/L	81.0 (47.0)	77.0 (43.5, 96.0)	75.5 (39.9)	66.0 (47.5, 99.5)
ASAT, U/L	24.3 (8.83)	24.0 (19.0, 26.0)	22.6 (6.93)	20.0 (18.0, 25.5)
ALAT, U/L	25.4 (9.64)	24.0 (20.0, 27.0)	27.9 (17.3)	22.0 (17.5, 31.0)
Creatinine, μmol/L	66.4 (11.4)	67.0 (56.5, 74.5)	69.0 (11.9)	72.0 (60.5, 76.5)
Resting metabolic rate, kcal/d	2016 (279)	2016 (1814, 2131)	1944 (288)	1944 (1728, 2145)
Respiratory quotient	0.79 (0.05)	0.79 (0.76, 0.83)	0.79 (0.03)	0.79 (0.77, 0.81)

¹Abbreviations: ALAT, alanine aminotransferase; ASAT; aspartate aminotransferase; HDL; High-density lipoprotein, LDL; low-density lipoprotein; SAAR, sulfur amino acid restriction; All variables are mean (standard deviation) and median (IQR) except row for males.

Table 2. Effects of SAAR on body weight, body composition and resting metabolic rate¹.				
	4 weeks		8 weeks	
	β (95% CI) SAAR vs. control	p-value	β (95% CI) SAAR vs. control	p-value
Body weight, kg	-0.70 (-1.6, 0.21)	0.13	-1.14 (-2.04, -0.25)	0.012
BMI, kg/m ²	-0.19 (-0.49, 0.12)	0.23	-0.30 (-0.60, 0.00)	0.049
Body fat, %	-0.08 (-0.66, 0.51)	0.79	0.01 (-0.57, 0.59)	0.98
Total fat, kg	-0.30 (-1.01, 0.42)	0.41	-0.40 (-1.11, 0.31)	0.27
Arm fat, kg	-0.03 (-0.15, 0.09)	0.67	-0.02 (-0.14, 0.09)	0.68
Leg fat, kg	-0.10 (-0.39, 0.19)	0.50	-0.15 (-0.44, 0.14)	0.31
Trunk fat, kg	-0.13 (-0.67, 0.40)	0.62	-0.20 (-0.73, 0.33)	0.46
Android fat, kg	0.01 (-0.10, 0.13)	0.80	-0.05 (-0.17, 0.06)	0.38
Gynoid fat, kg	-0.03 (-0.16, 0.10)	0.66	-0.12 (-0.26, 0.01)	0.060
Visceral adipose tissue, kg	0.05 (-0.03, 0.14)	0.21	0.02 (-0.06, 0.11)	0.57
Subcutaneous adipose tissue, kg	-0.03 (-0.13, 0.07)	0.55	-0.08 (-0.17, 0.02)	0.12
Fat free mass, kg	-0.38 (-0.87, 0.12)	0.13	-0.69 (-1.18, -0.20)	0.013
Resting metabolic rate, kcal/d	57.1 (-19.4, 134)	0.14	15.2 (-60.4, 90.7)	0.69
Fat oxidation, g/d	20.0 (1.82, 38.2)	0.031	12.8 (-5.12, 30.7)	0.16
Carbohydrate oxidation, g/d	-21.5 (-58.3, 15.3)	0.25	-17.9 (-54.2, 18.3)	0.33
Respiratory quotient	-0.01 (-0.03, 0.01)	0.20	-0.01 (-0.03, 0.01)	0.22

¹ β-estimates and p-values are derived from linear mixed models with body mass as the outcome, and group, visit and their interaction term (group × time) at 4 and 8 weeks as predictors. The models were baseline adjusted. The p-value indicates the difference between groups at each timepoint. Abbreviations: BMI, body mass index; SAAR, sulfur amino acid restriction

Table 3. Effects of SAAR on body weight, body composition and resting metabolic rate¹.				
	4 weeks		8 weeks	
	β (95 % CI) SAAR vs. control	p-value	β (95 % CI) SAAR vs. control	p-value
<i>Urinary sulfur amino acids</i>				
Methionine excretion, mmol/24h	-3.84 (-5.96, -1.72)	< 0.001	-2.70 (-4.86, -0.55)	0.014
tHcy excretion, mmol/24h	-3.03 (-4.80, -1.26)	< 0.001	-3.04 (-4.84, -1.24)	< 0.001
Cystathionine excretion, mmol/24h	-30.4 (-46.7, -14.1)	< 0.001	-32.2 (-48.8, -15.6)	< 0.001
tCys excretion, mmol/24h	-52.7 (-101, -4.66)	0.03	-77.3 (-126, -28.4)	< 0.001
Sulfate excretion, mol/24h	-22.3 (-26.9, -17.7)	< 0.001	-20.2 (-24.9, -15.6)	< 0.001
<i>Plasma sulfur amino acids</i>				
Plasma methionine, μmol/L	-0.60 (-2.30, 1.11)	0.49	-1.26 (-2.94, 0.43)	0.14
Plasma tHcy, μmol/L	1.87 (1.01, 2.73)	< 0.001	2.07 (1.22, 2.92)	< 0.001
Plasma cystathionine, μmol/L	-0.16 (-0.23, -0.09)	< 0.001	-0.16 (-0.23, -0.09)	< 0.001
Plasma tCys, μmol/L	13.0 (-2.17, 28.1)	0.09	12.3 (-2.67, 27.3)	0.11
<i>Plasma biomarkers</i>				
Triglycerides, mmol/L	0.01 (-0.17, 0.20)	0.90	-0.13 (-0.32, 0.05)	0.15
Total cholesterol, mmol/L	0.05 (-0.26, 0.36)	0.75	-0.07 (-0.38, 0.24)	0.67
LDL, mmol/L	-0.02 (-0.26, 0.23)	0.90	-0.05 (-0.29, 0.2)	0.70
HDL, mmol/L	0.05 (-0.05, 0.14)	0.35	0.05 (-0.04, 0.15)	0.29
Apolipoprotein B, g/L	0.01 (-0.07, 0.09)	0.78	-0.01 (-0.09, 0.07)	0.76
Apolipoprotein A1, g/l	0.03 (-0.06, 0.11)	0.52	-0.01 (-0.09, 0.07)	0.82
Fasting glucose, mmol/L	0.00 (-0.19, 0.18)	0.98	-0.07 (-0.25, 0.11)	0.42
<i>Plasma/serum hormones</i>				
Fasting insulin, pmol/L	-2.24 (-19.3, 14.8)	0.80	-9.24 (-26.1, 7.62)	0.28
C-peptide, pmol/L	1.49 (-94.8, 97.7)	0.98	-59.4 (-155, 35.7)	0.22
TSH, mU/L	-0.07 (-0.40, 0.27)	0.70	-0.30 (-0.63, 0.03)	0.08
Free T4, pmol/L	0.08 (-1.17, 1.33)	0.90	-0.29 (-1.53, 0.95)	0.64
FGF-21, pg/mL ²	-124 (-503, 256)	0.52	-83.3 (-460, 294)	0.66
IGF-1, pg/mL	-		-11.4 (-41.7, 18.9)	0.46
Adiponectin, pg/mL	-		-1.43 (-4.43, 1.58)	0.35
Gastric inhibitory peptide, pg/mL	-11.5 (-68.5, 45.6)	0.69	23.9 (-32.7, 80.4)	0.41
Glucagon-like peptide 1, pg/mL	-11.7 (-21.3, -2.11)	0.017	-7.82 (-17.3, 1.70)	0.11
Ghrelin, pg/mL	-6.36 (-46.8, 34.0)	0.76	-11.7 (-51.8, 28.3)	0.56
Leptin, ng/mL	-4.06 (-9.53, 1.40)	0.14	-6.01 (-11.4, -0.59)	0.030
Pancreatic peptide, pg/mL	39.3 (-26.8, 105)	0.24	47.3 (-18.4, 113)	0.16
Peptide YY, pg/mL	-5.90 (-18.8, 6.99)	0.37	-0.69 (-13.5, 12.1)	0.91
<i>Ketone bodies</i>				
β-hydroxybutyrate, μmol/L	46.7 (-54.9, 148)	0.37	117 (16.0, 217)	0.023
Acetoacetate, μmol/L	11.2 (-15.0, 37.4)	0.40	27.0 (1.04, 52.9)	0.042
Acetone, μmol/L	6.33 (-7.19, 19.9)	0.39	3.67 (-9.71, 17.1)	0.085
Acetate, μmol/L	4.28 (-5.45, 14.0)	0.36	8.45 (-1.18, 18.1)	0.59
<i>Safety markers</i>				
ASAT, U/L	3.20 (-0.91, 7.31)	0.13	0.76 (-3.27, 4.79)	0.71
ALAT, U/L	1.44 (-5.17, 8.06)	0.67	-1.89 (-8.44, 4.65)	0.57

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Urea, mmol/L	-0.27 (-0.63, 0.09)	0.14	-0.10 (-0.46, 0.26)	0.59
Creatinine, $\mu\text{mol/L}$	3.82 (1.09, 6.54)	0.008	3.67 (0.97, 6.37)	0.009
Vitamin B12, pmol/L	54.5 (-2.86, 112)	0.06	9.31 (-47.4, 66.1)	0.75
MMA, $\mu\text{mol/L}$	0.00 (-0.03, 0.04)	0.85	0.03 (-0.01, 0.06)	0.17

[†] β -estimates and p-values are derived from linear mixed models with body mass as the outcome, and group, visit and their interaction term (group \times time) at 4 and 8 weeks as predictors. The models were adjusted for baseline values of the outcome.

The p-values indicate the difference between groups at each timepoint.

Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate amino transferase; BMI, body mass index; FGF-21, fibroblast growth-factor 21; IGF-1, insulin-like growth factor 1; MMA, methylmalonic acid; SAAR, sulfur amino acid restriction; SE, standard error; tCys, total cysteine; tHcy, total homocysteine; TSH, thyroid stimulating hormone

Table 4: Significantly differentially expressed genes ranked by Log2 fold-change

Symbol	Gene name	Log2 fold-change	FDR
HSFX2	heat shock transcription factor family, X-linked 2	-1.41	0.019
ESM1	endothelial cell specific molecule 1	-1.15	0.002
SIK1B	salt inducible kinase 1B (putative)	-0.97	0.024
APLN	apelin	-0.85	0.018
LDOC1	LDOC1 regulator of NFkB signaling	-0.47	0.006
DGAT2	diacylglycerol O-acyltransferase 2	-0.46	0.006
GPAM	glycerol-3-phosphate acyltransferase, mitochondrial	-0.44	0.024
DLL4	delta like canonical Notch ligand 4	-0.40	0.007
MEGF9	multiple EGF like domains 9	-0.40	0.024
ISYNA1	inositol-3-phosphate synthase 1	-0.39	0.004
TBX6	T-box transcription factor 6	-0.39	0.045
CD34	CD34 molecule	-0.36	0.009
ELOVL5	ELOVL fatty acid elongase 5	-0.32	0.006
RFLNB	refilin B	-0.32	0.01
STK40	serine/threonine kinase 40	-0.27	0.034
SLC35G1	solute carrier family 35 member G1	-0.26	< 0.001
ACBD4	acyl-CoA binding domain containing 4	-0.19	0.009
ZSWIM7	zinc finger SWIM-type containing 7	-0.14	0.018
ANLN	anillin, actin binding protein	-0.12	< 0.001
PPM1N	protein phosphatase, Mg ²⁺ /Mn ²⁺ dependent 1N (putative)	-0.12	0.013
NOLC1	nucleolar and coiled-body phosphoprotein 1	-0.06	0.024
SPTA1	spectrin alpha, erythrocytic 1	-0.05	0.007
KIAA1324	endosome-lysosome associated apoptosis and autophagy regulator 1	-0.04	< 0.001
TBC1D1	TBC1 domain family member 1	-0.03	0.04
JMJD7-PLA2G4B	JMJD7-PLA2G4B readthrough	-0.02	0.024
MAP7D3	MAP7 domain containing 3	0.00	0.025
SLC25A24	solute carrier family 25 member 24	0.01	< 0.001
ITFG1	integrin alpha FG-GAP repeat containing 1	0.01	0.04
TEF	TEF transcription factor, PAR bZIP family member	0.02	0.019
NUMA1	nuclear mitotic apparatus protein 1	0.03	0.002
LARS2	leucyl-tRNA synthetase 2, mitochondrial	0.04	0.04
SEMA4A	semaphorin 4A	0.05	0.035
LRRC37A7P	leucine rich repeat containing 37 member A7, pseudogene	0.08	0.036
LRCC1	leucine rich repeat and coiled-coil centrosomal protein 1	0.09	0.024
SETBP1	SET binding protein 1	0.12	0.016
TNS1	tensin 1	0.13	< 0.001
LYG1	lysozyme g1	0.14	0.007
TENT5A	terminal nucleotidyltransferase 5A	0.16	0.034


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

HDAC9	histone deacetylase 9	0.16	0.048
TRPS1	transcriptional repressor GATA binding 1	0.22	0.023
ADH1B	alcohol dehydrogenase 1B (class I), beta polypeptide	0.23	0.008
CYP4B1	cytochrome P450 family 4 subfamily B member 1	0.33	< 0.001
ARID5B	AT-rich interaction domain 5B	0.37	0.009
HIST2H4A	novel transcript, antisense HIST2H4A	0.41	0.024

Abbreviations: FDR, false discovery rate


A

Study design




B

Change in sulfate excretion




D

Change in energy expenditure and substrate oxidation




C

Change in body weight and composition




E

Change in hormones



F


Change in ketone bodies



● Control ● SAAR


A

Change in sulfur amino acid excretion



B


Change in plasma sulfur amino acids



● Control ● SAAR


A

**Differentially expressed genes in adipose tissue after 8 weeks
SAAR vs. controls**



B

Top 10 upregulated GO terms



C

Top 10 downregulated GO terms

